IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation ...

IRVINE, Calif.--(BUSINESS WIRE)-- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing a novel implantable rechargeable sacral ...

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX) a medical technology company focused on the development and commercialization of novel implantable Sacral ...

Among Largest Rural Health Systems in the U.S. “I appreciate the commitment Axonics has made to innovate in this space,” said Kevin Benson, M.D., a urogynecologist at Sanford Health who also served as ...

IRVINE, Calif.--(BUSINESS WIRE)-- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation ...

An Axonics sacral neuromodulation system sends electrical signals to nerves in the spinal cord to help regulate the bladder and bowels Device maker Axonics Inc. says its newest system designed to ...

The FDA granted premarket approval for the Axonics r-SNM System as a treatment for urinary urge incontinence, urinary urge frequency, as well as urinary retention (OAB). It's fully rechargeable. It's ...

A new rechargeable sacral neuromodulation (SNM) system, InterStim Micro (Medtronic), was launched in the UK when Axonics SNM system was being assessed. The clinical experts explained that InterStim ...

Barely 6 months after raising a $38.5 million Series B to advance its neuromodulation implant to treat overactive bladder and fecal dysfunction, Axonics Modulation Technologies won a CE mark for the ...

Axonics today announced its R20 rechargeable sacral neuromodulation (SNM) system has received CE Mark approval for use in adults with overactive bladder and/or fecal incontinence. The implant can last ...

Axonics Modulation Technologies Inc. Chief Executive Ray Cohen is nothing if not confident about becoming the market leader in his urology device category, despite renewed competition from medtech ...

Evidence supports the case for adopting Axonics sacral neuromodulation (SNM) system for treating refractory overactive bladder in the NHS. Axonics SNM system improves symptoms and quality of life. It ...